Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Neutral 49.5%

Neg 0% Neu 49.5% Pos 0%

Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $50 to $60.